News

The Pharma Letter4h
ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemia vera
US drugmaker Protagonist Therapeutics (Nasdaq: PTGX) and Japan’s Takeda Pharma (TYO:4502) announced detailed results from the ...
The Pharma Letter3h
Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg
Arcus Biosciences (NYSE: RCUS) is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early ...
The Pharma Letter4h
Enhertu posts survival boost in second-line gastric cancer trial
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...
The Pharma Letter4h
ASCO: Pfizer’s Braftovi combo regimen cuts risk of death
The data showed a surprisingly compelling overall survival (OS) benefit. TheBraftovi combination regimen received Food and ...
The Pharma Letter3h
Imfinzi regimen shows early promise in hard-to-treat cancer
AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...
The Pharma Letter4h
Sandoz launches first interchangeable denosumab biosimilars in USA
Swiss generic and biosimilar medicines company Sandoz (SWX: SDZ) today announced that Wyost (denosumab) and Jubbonti ...
The Pharma Letter4h
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant
Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...
The Pharma Letter4h
IGBA welcomes ICH new topic for harmonization on biosimilars development
In a website posting, the International Generic and Biosimilar medicines Association (IGBA) has commended the General ...
The Pharma Letter4h
Vima Therapeutics
A clinical-stage biotech company developing oral therapies for movement disorders, with an initial focus on dystonia.
The Pharma Letter5h
Danish report recommends action on rare disease drugs
Treating greater numbers of Danish patients with rare diseases requires a more open and shared dialogue about handling ...
The Pharma Letter9h
iOnctura bolsters executive team as it advances Phase II cancer trials
Swiss biotech iOnctura has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer, ...
The Pharma Letter4h
Sanofi to fork out $9 million + to buy Blueprint Medicines
French pharma major Sanofi (Euronext: SAN) today revealed an agreement to acquire, and Blueprint Medicines (Nasdaq: BPMC), a US company, specializing in systemic mastocytosis (SM), a rare ...